Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathrine Leonowens

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology in Drug Development|November 4, 2022
Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal ImpairmentCathrine Leonowens, Virginia Schmith, Jie Zhou, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolitesDaniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 26, 2024
MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysisMarilyn A Huestis, William B Smith, Cathrine Leonowens, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2016
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanomaDaniele Ouellet, Nastya Kassir, Joannellyn Chiu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 28, 2019
Indinavir Increases Midazolam <i>N</i>-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo ApproachDan-Dan Tian, Cathrine Leonowens, Emily J Cox, et al.
British Journal of Clinical Pharmacology|March 11, 2014
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursCathrine Leonowens, Carolyn Pendry, John Bauman, et al.
Journal of Clinical Anesthesia|June 26, 2020
Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjectsJie Zhou, Cathrine Leonowens, Vijay D Ivaturi, et al.
Cancer Research Communications|November 12, 2024
Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple MyelomaTodd Shearer, Melissa Comstock, Rex L Williams, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology in Drug Development|November 4, 2022
Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal ImpairmentCathrine Leonowens, Virginia Schmith, Jie Zhou, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolitesDaniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 26, 2024
MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysisMarilyn A Huestis, William B Smith, Cathrine Leonowens, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2016
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanomaDaniele Ouellet, Nastya Kassir, Joannellyn Chiu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 28, 2019
Indinavir Increases Midazolam <i>N</i>-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo ApproachDan-Dan Tian, Cathrine Leonowens, Emily J Cox, et al.
British Journal of Clinical Pharmacology|March 11, 2014
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursCathrine Leonowens, Carolyn Pendry, John Bauman, et al.
Journal of Clinical Anesthesia|June 26, 2020
Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjectsJie Zhou, Cathrine Leonowens, Vijay D Ivaturi, et al.
Cancer Research Communications|November 12, 2024
Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple MyelomaTodd Shearer, Melissa Comstock, Rex L Williams, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Pageof 1